Blog
May 15, 2023
Poster sessions at AACR: a recap
We were grateful for the opportunity to attend and present at the AACR Annual Meeting last week, where three of our scientists highlighted some of the exciting work happening in our Vancouver lab.
The FDA is now approving biomarker-informed therapies on a routine basis, yet there is significant disparity in patient access to molecular profiling that would match cancer patients to these targeted treatments.
Canexia Health’s Brady Davis recently moderated a panel during the Precision World Medicine Conference (PMWC) in Philadelphia, leading a discussion around providing equitable access to molecular testing within health system settings, from making the business case to reimbursement.
The panelists were:
- Thuy Phung | University of South Alabama
- Michael B Datto M.D., Ph.D.| DUHS Clinical Labs, Duke University Health System, Clinical Laboratories
- Peter Hulick, M.D. FACMG | Mark R Neaman Ctr. For Personalized Medicine, Northshore University Health System
For key takeaways, read our blog post or watch the full discussion here.
Recent Resources
Press
March 28, 2023
Imagia Canexia Health Announces Three Abstracts to be Presented at AACR Annual Meeting 2023 Highlighting the Company’s Latest Research Findings
Imagia Canexia Health announced that three abstracts highlighting the company’s new learnings and tools will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, Florida.
Webinar
March 27, 2023
Project ACTT Webinar
Project ACTT (Access to Cancer Testing and Treatment) in Response to COVID-19 was a joint effort led by Imagia Canexia Health and supported by Digital Supercluster and partner institutions.